Congressional Opposition to WISeR Model Demands Performance Data From CMS
A congressional coalition sent a letter on June 22 to Centers for Medicare and Medicaid Services (CMS) Administrator Mehmet Oz, M.D., expressing...
The Centers for Medicare & Medicaid Services (CMS) is expanding Medicare coverage for genetic testing through the MolDX program administered by Palmetto GBA.
CMS announced two new local coverage determinations (LCDs) to cover diagnostic tests used to evaluate and manage care for patients suspected of having hereditary transthyretin amyloidosis:
- Genetic Testing for Heritable Thoracic Aortic Disease (L39933)
- Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (L39935)
The LCDs will take effect Aug. 17 in 23 states.
Source:
https://www.cap.org/advocacy/latest-news-and-practice-data/july-8-2025
Final Month of PAMA Reporting: Is Your Lab Ready?
July marks the final month of the 2026 PAMA reporting period. Laboratories that meet the definition of an applicable laboratory, which most do, have...
Humana Claims Payment Policies
Effective July 1, 2026, Humana will charge a $5.00 administrative fee for Medicare Advantage paper claim submissions.